Allan Z. Zhao and Fanghong Li, School of Biomedical and Pharmaceutical Sciences of Guangdong University of Technology, published a research paper entitled Targeted Deprivation of Methionine with Engineered Salmonella Leads to Oncolysis and Suppression of Metastasis in Broad types of Animal Tumor Models in Cell Reports Medicine, which entails the research of genetically engineered oncolytic bacteria SGN1 targeting the regulation of methionine metabolism in tumors, and explored its potential clinical value: dissolving tumors and inhibiting tumor metastasis in the treatment of broad-spectrum malignant tumors. The first authors of this paper are Dr. Zhou Sujin, Dr. Lin Yan and Dr. Zhao Zhenggang, all from School of Biomedical and Pharmaceutical Sciences, and the lead contacts are Prof. Allan Z. Zhao and Prof. Fanghong Li.
Prof. Zhao commented in an interview with Xinhua News Agency: This is a process from laboratory to clinical trial to medical achievement, as well as an independent innovative tumor treatment technology. In the next two to three years, the team will quickly promote the clinical trials of drugs on a number of tumor indications, especially for those malignant tumors that have no effective treatment drugs at present, hoping to bring a new solution to patients around the world in the future. This achievement has attracted the attention of the industry as Xinhua News Agency, Sina, Tencent among other media have made special reports.
